R

Revance

Biotech aesthetics company: neuromodulators and fillers

Executive Director - Head of Commercial & Enterprise Applications

Full-Time
$225k - $250k+ Performance bonus + Equity
Expert
Bachelor's, Master's, PhD
Nashville, TN, USA+4 moreMore locations: San Francisco, CA, USA | Los Angeles, CA, USA | Dallas, TX, USA | Johnson City, TN, USA
HybridHybrid, onsite role at one of the listed locations.
IT OperationsEnterprise Applications

About the job

Requirements
  • At least 12 years of progressive information technology experience, including at least 6 years leading enterprise application teams.
  • Deep hands-on Salesforce multi-cloud expertise across at least two of Marketing Cloud, Experience Cloud, Loyalty Cloud, and Service Cloud.
  • Working ownership of at least one of ERP (Aptean Ross or comparable), life sciences CRM (IQVIA OCE or Veeva), or contact center platforms (Five9 or comparable).
  • Full-lifecycle experience implementing or replatforming a major CRM or ERP, from selection and design through deployment and stabilization.
  • Experience owning the quote-to-cash or order-to-cash process end to end across CRM and ERP, including their integration.
  • Track record building high-performing internal teams while managing outsourced development and managed-services partners.
  • Demonstrated success implementing ITIL-based support models, DevOps practices, and quality-first delivery that measurably reduced incidents and rework.
  • Financial stewardship experience, including vendor spend management, license optimization, and building business cases for major initiatives.
  • Organizational change management experience driving adoption of new platforms and processes.
  • Ability to influence senior business stakeholders, communicate technical trade-offs in business terms, and manage competing priorities.
  • Bachelor's degree in Computer Science, Information Systems, or a related field required; advanced degree preferred.
  • Doctorate degree with 6 years of directly related experience, or Master's degree with 8 years of directly related experience, or Bachelor's degree with 10 years of directly related experience.
  • At least 5 years of managerial experience directly managing people, projects, programs, or resources.
Responsibilities
  • Own the Salesforce platform end to end, including Marketing Cloud, Experience Cloud, Loyalty Cloud, Service Cloud, and Commerce Cloud, together with the IQVIA OCE life sciences CRM used by the field force.
  • Ensure the CRM and Salesforce technology stack scales with the commercial business through a clean data model, configuration standards, and disciplined release practices.
  • Drive integration across the portfolio so platforms operate as one system and provide a seamless experience for the field, customers, and practices served.
  • Lead implementation of new commercial technology, including Salesforce Commerce upgrades and new platform capabilities, from business case through delivery and adoption.
  • Own Aptean Ross ERP and its order-to-cash flow, ensuring the commercial front end and ERP back end function as one process from quote through order, fulfillment, invoice, and cash.
  • Own the remaining application portfolio, including Five9 contact center, payment gateways, and sales training and marketing applications.
  • Lead and grow a team of business analysts, functional experts, solution architects, and project managers; establish standards for solution design, delivery, and documentation.
  • Direct third-party partners responsible for programming, customizations, and managed services; own statements of work, delivery quality, and vendor performance.
  • Partner with the Data & AI group's data engineering and integration team to define application-portfolio integration and data architecture, coordinate execution, and align with Aptean (Ross) and Salesforce vendors.
  • Partner with Commercial, Finance, Supply Chain, and Customer Service leaders to translate business strategy into an application roadmap with measurable outcomes.
  • Create and institutionalize continuous-improvement practices, reusable patterns, and governance that enable the portfolio to scale.
  • Use AI and automation to improve portfolio and IT operations, including intelligent ticket triage, automated testing, agent-assisted support, and workflow automation.
  • Evaluate emerging platform capabilities and rationalize the application landscape to reduce cost, complexity, and technical debt.
  • Lead business-process analysis and re-engineering with functional stakeholders before automation, ensuring solutions simplify processes rather than codify inefficiency.
  • Drive user adoption through structured change management, training, and stakeholder communication for every major release.
  • Measure post-go-live adoption and business value realization, and feed results into the roadmap.
  • Build support processes and a maturity roadmap focused on zero incidents through proactive monitoring, root-cause elimination, problem management, and resilient release practices.
  • Design solutions that minimize IT rework and error handling through requirements discipline, architectural guardrails, automated testing, and quality gates in the DevOps lifecycle.
  • Establish and report KPIs for system availability, incident and defect trends, delivery predictability, and business satisfaction; ensure business continuity and disaster-recovery readiness for core applications.
  • Coordinate with Security, CSV, and Compliance partners to meet regulatory and SOX obligations.
Desired Qualifications
  • Pharmaceutical, biotech, or life sciences commercial systems experience is strongly preferred.
  • Experience applying AI/ML and automation to IT operations and business-process improvement is a plus.

About the company

Revance Therapeutics develops neuromodulators and dermal fillers for the premium aesthetics market, with possible therapeutic uses for muscle movement and pain disorders. Its injectable products are used by healthcare professionals to reduce wrinkles and restore facial volume, improving patient outcomes. The company stands apart by pairing a portfolio of cosmetic injectables with HintMD, a fintech platform that streamlines payments and clinic management for aesthetic practices. Its goal is to lead the premium aesthetics space by offering differentiated injectables and expanding fintech-enabled services for practice efficiency.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1999

Get referred to Revance

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • SkinPen shipped over one million treatment kits since January 2025, proving practitioner demand.
  • PanOxyl won 2026 Allure Best of Beauty, strengthening consumer brand velocity.
  • Melissa O'Connor joined August 24, 2026, sharpening regulatory execution for new approvals.

What critics are saying

  • AbbVie won a $56 million DAXXIFY patent verdict on July 18, 2025.
  • Merger-related class actions continue through December 17, 2026, distracting management and inviting payouts.
  • Crown's $3.65 takeover and rebrand make Revance dependent on one owner for capital.

What makes Revance unique

  • DAXXIFY delivered fast onset and longer duration versus Botox on June 23, 2026.
  • Revance pairs injectables, SkinPen, and consumer skincare across 60 countries.
  • RHA Redensity Eye approved August 20, 2026, expands filler depth beyond glabellar lines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Unlimited Paid Time Off
  • 401(k) Company Match
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
GlobeNewswire
Aug 31st, 2026
Revelyx Bio launches to advance YY003, an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation.

Revelyx Bio launches to advance YY003, an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation. August 31, 2026 08:00 ET | Source: Revelyx Bio * Company aims to deliver the first FDA-approved recombinant botulinum neurotoxin type A (rBoNT/A) * Phase II study in moderate-to-severe glabellar lines completed; topline data expected in Q3 2026 * Dustin Sjuts, former President of Revance Therapeutics, has been appointed Chief Executive Officer, bringing 20 years of biopharma leadership in commercial strategy and product launches NASHVILLE, Tenn., Aug. 31, 2026 (GLOBE NEWSWIRE) - Revelyx Bio, Inc., a clinical-stage biopharmaceutical company, today announced its launch following an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd., for YY003, a ready-to-use liquid formulation of recombinant botulinum toxin type A (rBoNT/A). Under the terms of agreement, Revelyx holds exclusive rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong and Macau. Additionally, the company announced the appointment of Dustin Sjuts as Chief Executive Officer and member of its Board of Directors. "Revelyx is focused on combining YY003's differentiated science with a clear development path to bring next-generation recombinant innovation to an established, fast-growing market," said Dustin Sjuts, Chief Executive Officer of Revelyx Bio. "We will advance our lead asset with disciplined execution across clinical development, regulatory strategy and CMC as we prepare to report topline Phase II results and position the program for late-stage development." From Conventional Fermentation to Precision Genetic Engineering * YY003 is an investigational rBoNT/A formulated as a ready-to-use liquid and presented in a prefilled syringe. Produced via recombinant expression in E. coli rather than traditional Clostridium botulinum culture purification, the manufacturing process offers precise control over neurotoxin identity and purity. The resulting protein is structurally identical to naturally derived neurotoxin, offering the potential for high specific activity and enhanced safety profile. Recombinant manufacturing is a proven, highly scalable platform used to produce biologic medicines for over 40 years. * YY003 builds on Claruvis Pharmaceutical's proprietary recombinant platform, which also underpins Retoxin(R)(YY001). In March 2026, Claruvis secured approval from China's National Medical Products Administration (NMPA) for Retoxin(R) to temporarily improve moderate-to-severe glabellar lines in adults - marking the world's first approved rBoNT/A. Retoxin(R) is currently commercially available in China, with pivotal Phase III data published in Aesthetic Surgery Journal. Claruvis is also advancing Retoxin(R) in a Phase III trial in China for adult upper-limb spasticity secondary to stroke. Phase II Study of YY003 in Moderate-to-Severe Glabellar Lines Completed * The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug application for YY003 in September 2024. * A randomized, double-blind, vehicle-controlled Phase II study of YY003 in adults with moderate-to-severe glabellar lines has been completed at clinical sites in Australia. * Revelyx expects to report topline results in Q3 2026. "Having founded and led BioBAY, I have seen firsthand the quality and scale of innovation emerging from China's biotechnology ecosystem," said Xianghong Lin, Founding Partner of NRL Capital and original Founder of BioBay. "NRL incubated Revelyx to bring that innovation to global markets by pairing high-potential clinical programs with robust development, regulatory, CMC and commercial leadership required to advance them. YY003 is a compelling first example of this strategy, and Dustin brings the ideal operating experience and vision to lead it through the next stages of global growth." Mr. Sjuts brings over 20 years of experience building and scaling public and private life sciences companies. Through his career, he has advanced biologics, specialty pharmaceuticals and medical technologies from clinical development through manufacturing and commercialization, with deep expertise in injectable therapies and neuromodulators. Most recently, Mr. Sjuts served as President of Revance Therapeutics, where he oversaw commercial, clinical, regulatory and technical operations. During his tenure, he led the FDA approvals and U.S. commercial launches of DAXXIFY(R)(daxibotulinumtoxinA-lanm) for moderate-to-severe glabellar lines and cervical dystonia in adults, as well as the U.S. commercial launch of the RHA(R) Collection of dermal fillers. Before becoming President, he served as the company's Chief Commercial Officer. Earlier, Mr. Sjuts led Galderma's aesthetics business in Greater China from Shanghai and held commercial leadership roles at Allergan. About Revelyx Bio Revelyx Bio, Inc. is a private, clinical-stage biopharmaceutical company developing and advancing differentiated therapies sourced from Asia-Pacific innovators for the United States and other global markets. The company combines selective in-licensing with expertise in clinical development, regulatory strategy, chemistry, manufacturing and controls (CMC), and commercialization. Its lead program, YY003, is an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation being developed for aesthetic and therapeutic indications. Revelyx holds exclusive rights to develop and commercialize YY003 in all territories outside mainland China, Hong Kong and Macau. Learn more at www.revelyx.com or connect with us on LinkedIn. About Claruvis Chongqing Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, is a biopharmaceutical company dedicated to developing recombinant botulinum toxin products for aesthetic and therapeutic indications. Claruvis developed Retoxin(R)(YY001), the world's first approved recombinant botulinum toxin type A (rBoNT/A), and continues to advance a robust pipeline powered by its proprietary recombinant neurotoxin technology. For more information, visit MingMed Biotechnology at https://www.ming-med.com/en. Trademarks DAXXIFY(R) is a registered trademark of Revance Therapeutics, Inc. RHA(R) is a registered trademark of TEOXANE SA. Retoxin(R) is a registered trademark of Chongqing Claruvis Pharmaceutical Co., Ltd. Media Inquiries A photo accompanying this announcement is available here.

PR Newswire
Aug 24th, 2026
Revance appoints Melissa O'Connor as senior vice president, global regulatory

Revance, a global aesthetics and skincare company, has appointed Melissa O'Connor as senior vice president, global regulatory. O'Connor will report to chief operating officer Nick Crowe and lead the company's global regulatory strategy and organisation. O'Connor brings more than 25 years of experience spanning medical devices, combination products, biologics and human tissue-based products. She holds a Regulatory Affairs Certification and was named a RAPS Fellow in 2022. Most recently, O'Connor served as founding member and chief quality and regulatory officer at StimLabs, where she led quality and regulatory affairs for human tissue-based allografts and medical devices. She previously held regulatory and quality leadership roles at QSpex Technologies and Chemence Medical Products. Revance operates in 60 countries with a portfolio including DAXXIFY, RHA dermal fillers and consumer skincare brands such as PanOxyl and Blue Lizard.

PR Newswire
Aug 20th, 2026
FDA approves RHA Redensity Eye for undereye hollowing with 12-month results

Revance and Teoxane have received FDA approval for RHA Redensity Eye, a hyaluronic acid filler designed to treat moderate to severe undereye hollowing in adults aged 22 and older. The product delivers results lasting up to 12 months. The approval follows positive results from a 52-week US pivotal clinical study, where 93% of patients showed aesthetic improvement at three months. The study achieved 12-month results without touch-ups. RHA Redensity Eye exhibited a favourable safety profile with no late-onset or serious treatment-related adverse events. The product uses Teoxane's proprietary Preserved Network Technology, a gentle manufacturing process designed to preserve the natural structure of hyaluronic acid. RHA Redensity Eye is the first hyaluronic acid gel to demonstrate effectiveness using patient-reported outcomes as a co-primary endpoint in a US clinical study for the infraorbital region.

PR Newswire
Aug 17th, 2026
Revance appoints Janelle Wichmann as chief marketing officer for skincare division

Revance, a global aesthetics and skincare company, has appointed Janelle Wichmann as chief marketing officer for skincare. Wichmann will report to chief executive officer Nadeem Moiz and lead the company's skincare marketing strategy, brand development and commercial growth initiatives. Wichmann brings over 15 years of leadership experience in beauty, skincare and consumer health. She previously held senior roles at Ulta Beauty and Procter & Gamble, where she helped scale Native and led a turnaround of Olay North America. Her accolades include a Cannes Silver Lion and P&G's Beauty Marketer of the Year. In her new role, Wichmann will oversee efforts to strengthen Revance's skincare portfolio and spearhead consumer skincare digital, e-commerce and loyalty initiatives. Revance's skincare brands include PanOxyl, Blue Lizard, StriVectin and others.

Modern Aesthetics
Mar 31st, 2026
SkinPen milestone highlights growth in microneedling demand.

SkinPen milestone highlights growth in microneedling demand. 03/31/2026 Key Takeaways * Revance reported distributing more than 1 million SkinPen treatment kits since January 2025. * Growth follows the launch of SkinPen Precision Elite and reflects increasing demand for microneedling. * The company introduced a patient rebate program to support continued adoption. Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company's microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the device. SkinPen is positioned as a leading microneedling platform in the United States, with the Precision Elite device designed to enhance consistency and provider control through updated balance and ergonomics. According to the company, the system builds on earlier versions of SkinPen, which are used for mechanical microneedling procedures intended to improve skin appearance with minimal downtime. "Reaching 1 million SkinPen treatment kits sold since January 2025 is a powerful proof point - not only for SkinPen, but for the rapid growth of microneedling as an in-demand aesthetic treatment," said Nadeem Moiz, Chief Executive Officer of Revance. "This momentum reflects our continued commitment to advancing the category through innovation, education, and clinically supported outcomes." To coincide with the milestone, Revance launched the "$100 Reasons to Love SkinPen" rebate program, offering patients $100 off a series of 3 or more treatments between February 1 and June 30, 2026. The company stated that the initiative is intended to support patient access and continued utilization.